Third-quarter 13F filings show continued confidence in Eli Lilly’s long-term growth story. Ascent Group LLC boosted its position by 3.3%, acquiring an additional 575 shares to reach 17,821 shares worth approximately $13.6 million. Vanguard Group added 1.5% to its stake, now holding over 80 million shares, while Laurel Wealth Advisors grew its stake by an extraordinary 78,621%, ending the period with 11.55 million shares. Collectively, institutional investors and hedge funds own more than 82% of the outstanding shares, underscoring broad support from large fiduciaries even after recent market volatility.

In Q3, Eli Lilly reported adjusted earnings per share of $7.02, exceeding consensus estimates by $0.60, and revenue of $17.6 billion, topping forecasts by over $1.5 billion. This represented a year-over-year revenue increase of 53.9%, driven by strong demand for oncology and diabetes treatments. Management raised full-year EPS guidance to a range of 23.00–23.70, up from prior guidance of 22.70–23.20, signaling confidence in continued margin expansion and robust product launches in the pipeline.

Eli Lilly’s board approved a quarterly dividend increase to $1.73 per share, up from $1.50, representing an annualized payout of $6.92 and a payout ratio near 29%. This marks the 10th consecutive year of dividend growth and delivers a yield of approximately 0.6%—more than double the average yield in the S&P 500 health-care sector. Management has reaffirmed its commitment to returning capital through dividends and share repurchases, supported by a strong balance sheet and free cash flow generation exceeding $12 billion year-to-date.

Wall Street research remains constructive, with 21 Buy ratings and four Hold ratings from major brokerages. The consensus EPS estimate for FY 2026 stands at 24.50, implying mid‐single-digit growth over raised FY 2025 guidance. Price targets range from $950 to $1,200, reflecting a forward P/E multiple in line with the biotechnology peer group and potential upside from late-stage pipeline assets including novel oncology antibody-drug conjugates and next-generation immuno-oncology candidates.